Shengguang Zhao

机构：Ruijin Hospital, Shanghai Genon Biological Products (China) · ORCID：0000-0001-7116-692X

发表论文 57 篇 · 总被引 684 次 · h-index 10

代表论文

• CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (2024 · European Radiology · 被引 20)
• A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors (2024 · Frontiers in Immunology · 被引 19)
• Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2) (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort (2024 · BMC Cancer · 被引 6)
• Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial (2024 · BMC Medicine · 被引 5)
• Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 4)